Aim:

To investigate how erectile dysfunction (ED) medications affect morning erection in patients with ED and how they respond to the return of morning erection.

Methods:

This study was conducted in 120 patients who experienced successful intercourse with either tadalafil or sildenafil. Using a random face-to-face interview and a questionnaire (about the quality and number of days getting morning erection after using the two medications), the impact of the medications on the morning erections was investigated, and the participants were asked about their feelings on regaining morning erection.

Results:

Of the respondents, 81% (68% of those with sildenafil and 99% of those with tadalafil) experienced morning erections after taking an oral ED medication. The men who took tadalafil mainly for 2 days with one dose, while those who took sildenafil experienced morning erections mainly for 1 day. The major sentiment upon regaining a morning erection was, "having more confidence as a man" (74%). Among the 96 respondents who experienced morning erections with tadalafil, 52% preferred tadalafil over sildenafil, not only because of freedom from concerns about a specific time to have relations, but also regaining morning erection.

Conclusion:

Regaining a morning erection affects the recovery of confidence as a man and influences the preference for tadalafil over sildenafil.

References

1. Fisher C, Gross J, Zuch J. Cycle of penile erections synchronous with dreaming (REM) sleep. Preliminary report. Arch Gen Psychiatry 1965; 12: 29–45. | PubMed | ChemPort |
2. Karacan I, Salis PJ, Williams RL. The role of the sleep laboratory in diagnosis and treatment of impotence. In Williams RL, Karacan I, Frazier SH, editors. Sleep disorders: diagnosis and Treatment. New York: John Wiley & Sons; 1978. p 353–82.
3. Karacan I, Williams RL, Thornby JI, Salis PJ. Sleep related penile tumescence as a function of age. Am J Psychiatry 1975; 132: 932–7. | PubMed | ChemPort |
4. Gordon CM, Carey MP. Penile tumescence monitoring during morning naps to assess male erectile functioning: an initial study of healthy men of varied ages. Arch Sex Behav 1995; 24: 291–307. | Article | PubMed | ISI | ChemPort |
5. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121–5. | Article | PubMed | ISI |
6. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. NEnglJMed 1998; 338: 1397–404. | Article | ChemPort |
7. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93:1276–81. | Article | PubMed | ISI | ChemPort |
8. Eardley I, Brook J, Yates PK, Wulff MB, Boolell M. Sildenafil (Viagra™), a novel oral treatment with rapid onset of action for penile erectile dysfunction. Br J Urol 1997; 79 (Suppl 4): 66. | PubMed |
9. Padma-Nathan H, Giuliano F. Oral drug therapy for erectile dysfunction. Urol Clin North Am 2001; 28: 321–34. | Article | PubMed | ChemPort |
10. Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabe J, Burgess G, et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005; 47: 87–91. | Article | PubMed | ISI | ChemPort |
11. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323–32. | Article | PubMed | ISI | ChemPort |
12. von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, et al. A multicenter, radomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499–507. | Article | PubMed | ISI | ChemPort |
13. Porst H, Kleingarn M, Arnds S. The three PDE 5 inhibitors sildenafil, tadalafil and vardenafil - Results of a comparative preference trial in 222 patients with erectile dysfunction. J Urol 2004; 171 (suppl 4): 315.
14. Dean J, Hackett G, Gentile V, Farina F, Zhao Y, Harrison M, et al. Drug attributes influencing the choice of sildenafil citrate and tadalafil for the treatment of erectile dysfunction in an open label, crossover study. XVII World Congress of Sexology; 10–15 July, Montreal, Canada. Abstract No. 3144.
15. Swindle RW, Cameron AE, Lockhart DC, Rosen RC. The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. Arch Sex Behav 2004; 33: 19–30. | Article | PubMed | ISI |
16. Dean J, Hackett G, Gentile V, Farina F, Zhao Y, Harrison M, et al. Psychological and interpersonal outcomes in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction in an open label, crossover study. XVII World Congress of Sexology; 10–15, July, Montreal, Canada. Abstract No. 3133.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.